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Abstract
Background: Lobular carcinoma in situ (LCIS) of the breast is a risk factor of developing invasive breast cancer. We
evaluated the racial differences in the risks of subsequent invasive breast cancer following LCIS.
Methods: We utilized data from the Surveillance, Epidemiology, and End Results registries to identify 18,835
women diagnosed with LCIS from 1990 to 2015. Cox proportional hazards regression was used to estimate race/
ethnicity-associated hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) of subsequent invasive
breast cancer.
Results: During a median follow-up of 90 months, 1567 patients developed invasive breast cancer. The 10-year
incidence was 7.9% for Asians, 8.2% for Hispanics, 9.3% for whites, and 11.2% for blacks (P = 0.046). Compared to
white women, black women had significantly elevated risks of subsequent invasive breast cancer (HR 1.33; 95% CI
1.11, 1.59), and invasive cancer in the ipsilateral breast (HR 1.37; 95% CI 1.08, 1.72) and in the contralateral breast (HR
1.33; 95% CI 1.00, 1.76). Black women had significantly higher risks of invasive subtypes negative for both estrogen
receptor and progesterone receptor (HR 1.86; 95% CI 1.14, 3.03) and invasive subtypes positive for one or both of
receptors (HR 1.30; 95% CI 1.07, 1.59). The risk of subsequent invasive breast cancer was comparable in Asian
women and Hispanic women compared with white women.
Conclusions: Black women had a significantly higher risk of developing invasive breast cancer, including both
hormone receptor-positive and hormone receptor-negative subtypes, after LCIS compared with white counterparts.
It provides an opportunity to address health disparities.
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Background
Lobular carcinoma in situ (LCIS) is a pre-malignant
breast lesion that increases a woman’s long-term risk of
developing invasive carcinoma [1–5]. Compared to the
general population, women diagnosed with LCIS have a
3-fold to 10-fold higher risk of invasive breast carcinoma
[1–7]. The annual incidence of subsequent breast cancer
in women diagnosed with LCIS is 1 to 2% per year [6,
8]. LCIS is largely diagnosed in women between the ages
of 45 to 50 years old [8, 9]. LCIS does not commonly
present with palpable breast masses or calcification on
mammography; only 0.5 to 3.8% of benign breast biop-
sies are diagnosed with LCIS [7]. Prior analysis of Na-
tional Cancer Institute’s Surveillance, Epidemiology, and
End Results (SEER) data has shown that the age-
adjusted incidence of LCIS increased from 2.0 per 100,
000 in 2000 to 2.75 per 100,000 in 2009 [10]. This may
be due to increased surveillance and utilization of
mammography.
Although considered as low-risk pre-invasive or be-
nign lesions, controversy persists regarding whether to
classify LCIS as a precursor of subsequent invasive car-
cinoma or just as a lesion that increases the risk of
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breast cancer in a woman’s lifetime [1, 9, 11]. This ab-
normal proliferation of cells frequently originates in the
terminal ductal lobular unit of the breast and may
spread to the ducts [12]. LCIS may also be associated
with the development of invasive ductal carcinoma, typ-
ically estrogen receptor-positive (ER+) lesions [13].
Pathological models of breast cancer progression have
proposed distinct ductal and lobular pathways from nor-
mal breast tissue to invasive breast cancer [14]. Ductal
carcinoma in situ (DCIS) and LCIS are pre-invasive
breast lesions among the two proposed pathways to in-
vasive breast cancer. We and other groups have previ-
ously shown that among African American women,
DCIS is associated with excess risk of subsequent inva-
sive breast cancer when compared to white women [15–
20]. Potential racial differences in the risk of subsequent
invasive breast cancer following LCIS are far less under-
stood. In this study, we examined the associations be-
tween race/ethnicity and the risks of subsequent invasive
breast cancer in a population-based racially diverse
group of women with LCIS. Understanding of racial dif-
ferences in LCIS outcomes will contribute to the devel-
opment of patient management strategies and refine our




The cases included in this study were from the SEER
database. The data were derived from 17 SEER registries
which represent approximately 28% of the US popula-
tion. De-identified SEER data were utilized thus exempt-
ing the study from review by our Institutional Review
Board. The analysis included women diagnosed with pri-
mary unilateral LCIS (no concurrent DCIS) between
January 1990 and June 2015 who had no prior cancer
history, were aged 20 or older, and were followed for at
least 6 months (n = 20,021). Patients who underwent bi-
lateral mastectomy were excluded (n = 716). Race/ethni-
city was determined as mutually exclusive categories of
non-Hispanic white (hereafter acknowledged as white),
non-Hispanic black (black), non-Hispanic Asian (Asian),
and Hispanic. The analysis excluded Pacific Islanders
and other racial classifications (n = 470). Thus, 18,835
women with LCIS were included in the analysis.
Outcomes
The primary outcome of interest is subsequent invasive
breast cancer, defined as invasive breast cancer, regard-
less of histological features, in either of the breasts or
metastatic breast cancer that was diagnosed at least 6
months after the initial LCIS to ensure that it was not
part of the index LCIS [15]. Subsequent invasive breast
cancers were classified to ipsilateral and contralateral
invasive breast cancers. Subsequent invasive breast can-
cer was also subdivided by both ER and progesterone re-
ceptor (PR) status to examine the association between
race/ethnicity and risk of invasive subtypes defined by
both ER and PR.
Statistical analysis
To compare categorical and continuous variables across
racial/ethnic groups, we used the χ2 test and analysis of
variance, respectively. Person-years were calculated from
6months after the initial LCIS diagnosis until the diag-
nosis date of the second primary breast tumor (invasive
or carcinoma in situ), death, or December 2015. The
Kaplan-Meier estimates of 10-year probabilities of subse-
quent invasive breast cancer were computed for each of
the four race/ethnic groups, and log-rank tests were per-
formed to test for significant differences. We utilized the
Lunn-McNeil competing risk models, an extension of
the Cox proportional hazards regression models [21], to
estimate the race-associated hazard ratio (HR) and 95%
confidence interval (CI) of subsequent invasive breast
cancer. Subsequent carcinoma in situ was modeled as
separate competing outcomes. Specifically, each patient
had a separate observation for each type of outcomes
and the analysis was stratified on outcome types. Scaled
Schoenfeld residuals were used to confirm the assump-
tions of proportionality in Cox models. The risks of ipsi-
lateral and contralateral invasive breast cancer were
analyzed using two separate competing risk models. We
also analyzed subsequent invasive breast cancer subtypes
defined by both ER and PR in black and white women
using the aforementioned competing risk models; tu-
mors positive for ER and/or PR were classified as hor-
mone receptor-positive (ER+/PR+), and tumors negative
for both ER and PR were classified as hormone receptor-
negative (ER−PR−). Likelihood ratio tests for heterogen-
eity were used to determine statistically significant dif-
ferences in the associations of race/ethnicity with cancer
subtypes.
Each statistical model was adjusted for age (20–39,
40–49, 50–59, 60–69, or ≥ 70 years), year of LCIS diag-
nosis (1990–1999, 2000–2009, or 2010–2015), treatment
of LCIS (no surgical treatment, breast-conserving sur-
gery alone, breast-conserving surgery followed by radi-
ation therapy, unilateral mastectomy, bilateral
mastectomy, or unknown), and registries. The analyses
were stratified by age at the diagnosis of LCIS (< 50 years
vs ≥ 50 years). The interaction between race/ethnicity
and age at the diagnosis of LCIS was assessed by includ-
ing a cross-product term in multivariable-adjusted
models. The statistical significance of an interaction
term was evaluated by the likelihood ratio test. All statis-
tical analyses were conducted with SAS (9.4 version). A
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two-sided P < 0.05 was used to indicate statistical
significance.
Results
Among 18,835 women with LCIS, 78.6% were white,
8.2% were black, 4.6% were Asian, and 8.6% were His-
panic. Mean age was 54.1 (a range of 20–95). They were
followed for 90 months on average. While 9.9% of pa-
tients did not receive surgery, 83.0% had breast-
conserving surgery alone, 1.4% were treated with breast-
conserving surgery and radiation therapy, and 4.2% had
a unilateral mastectomy.
Table 1 presents the characteristics of patients by
race/ethnicity. Overall, women from racial/ethnic minor-
ity backgrounds were significantly younger at their LCIS
diagnosis. Asian women were more likely than the other
racial groups to undergo breast-conserving surgery
alone, while white women were more likely than racial
minority women to receive mastectomies.
Among 18,835 patients, 1567 (8.3%) subsequently de-
veloped invasive breast cancer in either breast (n = 1536)
or other body parts (stage IV, n = 31) during the 90-
month follow-up. Of these subsequent invasive tumors,
801 (51.1%) were ductal, 408 (26.0%) were lobular, and
242 (15.4%) had both lobular and other types of hist-
ology. We observed a significant racial/ethnic difference
(P = 0.046) in the cumulative incidence of subsequent in-
vasive breast cancer (Fig. 1a). The 10-year cumulative
risk of subsequent invasive breast cancer was 7.9% in
Asian women, 8.2% in Hispanic women, 9.3% in white
women, and 11.2% in black women. The multivariable-
adjusted RR of subsequent breast cancer was 1.33 (95%
CI 1.11, 1.59) in black women compared to white
women (Table 2). Asian and Hispanic women had a
similar risk compared to white women. We also exam-
ined the race-associated risk in patients diagnosed and
followed during three time intervals: between 1990 and
1999, between 2000 and 2009, and between 2010 and
2015 (Additional file 1: Table S1). The increased risk in
Table 1 Characteristics of women with lobular carcinoma in situ (LCIS) in the SEER by race and ethnicity, 1990 to 2015 (n = 18,835)
White Black Asian Hispanic
Number of cases 14,811 1536 865 1623
Age at diagnosis, %
Mean (SD) 54.7 (10.6) 53.3 (10.7) 51.0 (9.7) 51.5 (9.6)
20–39 3.3 5.7 6.2 5.3
40–49 32.9 34.8 45.4 44.4
50–59 35.3 34.1 31.7 31.0
60–69 17.7 16.8 11.2 13.7
≥ 70 10.8 8.6 5.4 5.6
Length of follow-up, %
Median (range), months 95 (6–311) 80 (6–309) 74 (6–310) 77 (6–311)
6–11 months 4.2 5.5 6.1 6.2
12–59months 27.3 32.7 35.1 33.8
60–119months 30.2 30.4 30.5 30.6
≥ 120months 38.3 31.5 28.2 29.4
Year of the first LCIS diagnosis, %
1990–1999 19.2 16.3 12.5 13.8
2000–2009 53.2 47.5 46.8 48.1
2010–2015 27.7 36.3 40.7 38.1
Treatment
No surgery 10.0 11.4 8.3 8.9
BCS alone 82.7 82.4 86.0 84.7
BCS and radiation 1.4 1.2 1.9 2.0
Mastectomy 4.5 3.5 2.8 3.2
Unknown 1.4 1.6 1.0 1.1
Abbreviations: SD standard deviation, BCS breast-conserving surgery, ER estrogen receptor, PR progesterone receptor
Race and ethnicity were classified into mutually exclusive categories of non-Hispanic white (hereafter referred to as white), non-Hispanic black (black), non-
Hispanic Asian (Asian), and Hispanic (Hispanic)
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black women was consistently observed over time.
The analysis of race-associated risk of subsequent in-
vasive breast cancer was also stratified by age at the
diagnosis of LCIS; there was no significant variation
in the association pattern between women diagnosed
under 50 years and those diagnosed at the age of 50
years and older (Additional file 2: Table S2). Among
the 17,843 women with breast-conserving surgery or
no definitive surgery, 909 (5.1%) had ipsilateral inva-
sive breast cancer during a median follow-up of 89
months (range 6-311 months). We observed no statis-
tically significant difference in the cumulative inci-
dence of ipsilateral invasive breast cancer by race/
ethnicity (P = 0.20; Fig. 1b). Multivariable-adjusted
analysis (Table 2) showed that black women had a
significantly higher risk of ipsilateral invasive breast
cancer when compared to white women (HR 1.37;
95% CI 1.08, 1.72). There was no significant
difference in the risk of ipsilateral invasive breast can-
cer between Hispanic, Asian, and white women.
Among the 18,642 patients who had known treatment
status, 635 (3.4%) patients were diagnosed with contra-
lateral invasive breast cancer during a median follow-up
of 91 months (range 6–311 months). There was no sig-
nificant difference in the cumulative incidence of contra-
lateral invasive breast cancer by race/ethnicity (P = 0.12;
Fig. 1c). The multivariable-adjusted HR of contralateral
invasive breast cancer in black women compared with
white women was 1.33 (95% CI 1.00, 1.76), which was
similar to the risk of subsequent invasive breast cancer
and the risk of ipsilateral invasive breast cancer (Table 2).
There was no significant difference in the risks of
contralateral breast cancer in Asian women and His-
panic women compared with white women.
An analysis of hormone receptor status in subsequent
invasive breast cancer was performed in white women
Fig. 1 Cumulative incidences of subsequent invasive breast cancer in either breast or other body parts (a), ipsilateral invasive breast cancer (b),
and contralateral invasive breast cancer (c) among four racial/ethnic groups of women with LCIS
Table 2 Risk of subsequent invasive breast cancer overall and by laterality associated with race and ethnicity in women with LCIS
Subsequent invasive breast cancera Ipsilateral invasive breast cancerb Contralateral invasive breast cancerc
Person-years Cases HRd (95% CI) Person-years Cases HRe (95% CI) Person-years Cases HRf (95% CI)
White 130,213 1264 1.00 120,334 722 1.00 128,949 521 1.00
Black 11,935 142 1.33 (1.11, 1.59) 11,283 85 1.37 (1.08, 1.72) 11,818 57 1.33 (1.00, 1.76)
Asian 6434 55 0.83 (0.62, 1.10) 6137 33 0.87 (0.61, 1.25) 6406 22 0.78 (0.49, 1.24)
Hispanic 12,229 106 0.89 (0.72, 1.09) 11,564 70 0.99 (0.77, 1.27) 12,142 36 0.76 (0.54, 1.08)
Abbreviations: HR hazard ratio, 95% CI 95% confidence interval
aSubsequent invasive breast cancer included invasive breast cancer in either breast and metastatic breast cancer. The analysis included 19,545 women with LCIS
bThe analysis was restricted to 17,843 women who did not have surgical treatment or received breast-conserving surgery for primary LCIS
cThe analysis was restricted to 18,642 women who did not have surgical treatment or received breast-conserving surgery or unilateral mastectomy for
primary LCIS
dHRs were adjusted for age (20–39, 40–49, 50–59, 60–69, or ≥ 70 years) and year of the initial LCIS diagnosis (1990–1999, 2000–2009, or 2010–2015), registry, and
treatment for primary LCIS (no surgical treatment, breast-conserving surgery alone, breast-conserving surgery followed by radiation therapy, mastectomy,
or unknown)
eThe covariates were the same as the above. Treatment was categorized as no surgical treatment, breast-conserving surgery alone, or breast-conserving surgery
followed by radiation therapy
fThe covariates were the same as the above. Treatment was categorized as no surgical treatment, breast-conserving surgery alone, breast-conserving surgery
followed by radiation therapy, or mastectomy
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and black women (n = 16,347) (Table 3). Black women
had significantly higher risks of ER−PR− invasive breast
cancer (HR 1.86; 95% CI 1.14, 3.03) and ER+/PR+ inva-
sive breast cancer (HR 1.30, 95% CI 1.07, 1.59) following
LCIS compared to white women. There was no signifi-
cant variation in the associations with these two sub-
types (Heterogeneity = 0.15).
Discussion
By utilizing SEER data from a racially diverse group of
women with LCIS, we assessed the association between
race/ethnicity and risks of subsequent invasive breast
cancer among 19,545 patients. Compared with white
women, black women had a significantly higher risk of
developing invasive breast cancer during the follow-up.
The risk of invasive breast cancer was increased by 37%
in the ipsilateral breast and increased by 33% in the
contralateral breast among black women. In addition,
black women had significantly higher risks of developing
ER+/PR+ and ER−PR− invasive breast cancer following
LCIS. Asian and Hispanic women did not display a sig-
nificant difference in the risk of acquiring subsequent in-
vasive breast cancer when compared to white women.
We observed a 10-year incidence of subsequent inva-
sive breast cancer that was 7.9% in Asian women, 8.2%
in Hispanic women, 9.3% in white women, and 11.2% in
black women. Other investigators have reported a simi-
lar cumulative long-term incidence of second breast tu-
mors after LCIS, but ignored associations with race. A
long-term follow-up study of 236 patients found that the
probability of developing subsequent invasive carcinoma
by 10 years after a diagnosis of LCIS was 13% [6].
Among 4853 women with LCIS identified from the
1973–1998 SEER database, there was a 7.1% minimum
risk of developing subsequent invasive breast tumors on
either the ipsilateral or contralateral breast [22]. Our
findings of a higher 10-year incidence of subsequent in-
vasive breast cancer among black women compared to
other races support further investigation of the biological
and non-biological factors that influence LCIS malig-
nancy potential.
We assessed receptor expression in subsequent invasive
breast cancer following LCIS between black women and
white women, identifying that black women had a signifi-
cantly higher risk for ER−PR− invasive subtypes. This cor-
related with other studies that have identified higher risks
of these receptor statuses in black women [23]. The obser-
vation of higher risk of ER−/PR− invasive tumors follow-
ing LCIS among black women is noteworthy due to the
aggressiveness of those lesions. In a nationally representa-
tive population of DCIS patients diagnosed between 1990
and 2015, we demonstrated that compared with white
women, the risk of developing ER−PR− invasive breast
cancer was significantly increased by 86% (HR = 1.86, 95%
CI 1.57–2.20) in black women and by 40% in Asian
women (HR = 1.40, 95% CI 1.14–1.71). The associations
for ER−/PR− invasive cancer were stronger than the asso-
ciations for ER+/PR+ subtypes (HR = 1.31, 95% CI 1.21–
1.43 in blacks; HR = 1.01, 95% CI 0.92–1.11 in Asians; Het-
erogeneity = 0.0004) [24]. Thus, the magnitude of the associ-
ations between black race and risk of invasive breast
cancer subtypes following LCIS and DCIS was similar.
Among women with benign breast disease, African
American identity was a significant risk factor for triple
negative breast cancer [25]. These findings warrant further
investigation of race-related biomarker profiling of pre-
malignant breast lesions.
Within this study, differing treatment options were
noted to be favored among patients of various races.
Breast-conserving surgery alone was chosen by 83.0% of
patients, 9.9% did not receive surgery, 4.2% had a unilat-
eral mastectomy, and 1.4% were treated with both
breast-conserving surgery and radiation therapy. Among
the patients who chose mastectomies, white women
were more likely to do so than women of racial minor-
ities, and among the patients who chose no surgical in-
terventions, black women were more likely to do so than
women in the other racial groups. These racial variations
in choices may be due to healthcare disparities, due to
greater preferences of a certain type of treatment based
on concomitant cultural norms, or due to the absence of
a standardized treatment for LCIS based on the uncer-
tainty regarding the lesion’s malignancy potential [26,
27]. The National Comprehensive Cancer Network
(NCCN) guidelines (2018) states that surgical treatment
is not required for classic LCIS but acknowledges clini-
cian’s choice to perform surgical excision with negative
margins for pleomorphic LCIS [26]. Considered as a
more aggressive subtype, pleomorphic LCIS contains
high-grade cytological features and usually is diagnosed
by calcifications on mammography [28].
Overall, NCCN guidelines recommend counseling pa-
tients on lifestyle modifications and follow-up
Table 3 Risk of subsequent hormone receptor-defined invasive
breast cancer in black women with LCIS compared with white
counterparts (n = 16,347)
Person-
years
ER+/PR+ ER− and PR−
Cases HRa (95% CI) Cases HRa (95% CI)
White 130,213 1056 1.00 129 1.00
Black 11,935 115 1.30 (1.07, 1.59) 20 1.86 (1.14, 3.03)
Heterogeneity = 0.15
Abbreviations: HR hazard ratio, 95% CI 95% confidence interval, ER estrogen
receptor, PR progesterone receptor
aHRs were adjusted for age (20–39, 40–49, 50–59, 60–69, or ≥ 70 years) and
year of the primary LCIS diagnosis (1990–1999, 2000–2009, or 2010–2015),
registry, and treatment for primary LCIS (no surgical treatment, breast-
conserving surgery alone, breast-conserving surgery followed by radiation
therapy, mastectomy, or unknown)
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surveillance appointments that include annual mam-
mography, physical examinations, and interval history
every 6 to 12 months [26]. As a strategy of risk reduc-
tion, LCIS patients with higher risk, such as women with
BRCA 1 or BRCA 2 genetic mutations, may undergo bi-
lateral prophylactic mastectomy [10]. There is limited
support for the addition of radiation therapy, but a small
cohort study suggested some benefits [13]. Based on the
more recent findings of Taylor et al. [29], there was no
significant difference in overall survival between patients
who received lumpectomy alone or lumpectomy with ra-
diation treatment. Thus, considering the healthcare costs
and potential health risk of radiation treatments, lump-
ectomy alone could be a more appropriate standardized
treatment.
Adjuvant therapy such as chemoprevention is an ef-
fective method to reduce patient’s risk of developing
breast cancer, specifically ER+ invasive breast cancer [30,
31]. The NSABP P-1 trial reported that tamoxifen re-
duced the incidence of invasive breast lesions from 42.5
per 1000 women in the placebo group to 24.8 per 1000
women in the treatment group [30]. The NCCN guide-
lines support the administration of tamoxifen, raloxifene,
and aromatase inhibitors for 5 years as a risk reduction
strategy in LCIS patients [26]. Chemoprevention has
been associated with improved quality-adjusted life ex-
pectancy in premenopausal women when compared to
postmenopausal women [32].
This study has limitations. SEER registries did not pro-
vide information regarding endocrine therapy utilization,
family cancer history, comorbidities, obesity, alcohol
consumption, breast cancer screening after LCIS, and
socioeconomic status, which may influence the risk of
second breast tumors. Although an adequate analysis
was conducted from the LCIS patient data, receptor sta-
tus in LCIS lesions, tumor grade, and tumor size infor-
mation were unavailable for more than half of patients
and thus were not accounted for in the analysis. Treat-
ment status was missing in less than 2% of patients.
Missing indicators were documented for this analysis.
This approach has been demonstrated to have no signifi-
cant impacts on the estimated associations between ex-
posures and cancer outcomes when missing is less than
50% [33].
Conclusions
Our study provides the largest population-based analysis
on the association between race/ethnicity and the devel-
opment of subsequent invasive breast cancer after LCIS
and for the first time addresses the risk of hormone
receptor-negative breast cancer following LCIS. Black
women with LCIS had an elevated risk of subsequent in-
vasive breast cancer, including both ER+/PR+ and ER
−PR− tumors. Asian and Hispanic women did not have
a higher risk of developing these lesions when compared
to white women. Further research may refine post-
treatment surveillance strategies and might better under-
stand racial preferences for and provider-patient com-
munications about LCIS treatment. In addition, studies
to identify which gene expression and molecular alter-
ations in LCIS are associated with the risk of developing
invasive carcinoma may open new pathways for chemo-
prevention and improve patient care to reduce the dis-
proportionate burden of breast cancer in black women.
These results also highlight the importance of under-
standing genetic background, early-life environmental/
behavioral exposures, and their interactions as contribu-
tors to racial differences in risk of developing invasive
breast cancer following LCIS.
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